This systematic review shows that approximately half of patients with ATS/ERS-defined severe asthma worldwide meet eligibility criteria for at least 1 biologic therapy targeting IgE, IL-5/IL-5Rα, or IL-4Rα. This evidence concerns the gene IL5RA and asthma.